Collaborative care for depression and anxiety disorders: results and lessons learned from the Danish cluster-randomized Collabri trials

Table 1 Overview of data

	Data collection method	6-months’ follow-up		15-months’ follow-up
	Data collection method	Depression trial	Anxiety trial	Depression trial	Anxiety trial
Primary outcomes
BDI-II	Self-reported	x
BAI	Self-reported		x
Secondary outcomes
BDI-II	Self-reported		x	x
BAI	Self-reported	x			x
SCL-90-R^a [20]	Self-reported	x	x	x	x
GAF [21]	Research assistant	x	x	x	x
Explorative outcomes
BDI-II	Self-reported				x
BAI	Self-reported			x
The Diagnostic Apathia Scale [22]	Research assistant	x	x	x	x
PSP [23]	Research assistant	x	x	x	x
SDS [24]	Self-reported	x	x	x	x
WHO-5 [25]	Self-reported	x	x	x	x
Personal Control^b [26]	Self-reported	x	x	x	x
Control/Manage Depression^c [27]	Self-reported	x	x	x	x
Obtain Help from Community, Family, Friends^c [27]	Self-reported	x	x	x	x
EQ-5D-3 L [28]	Self-reported	x	x	x	x
PRISE^d [29]	Self-reported	x	x	x	x
CSQ-8 [30]	Self-reported	x	x
INSPIRE-S [31]	Self-reported	x	x
INSPIRE-R [31]	Self-reported	x	x
Weeks on sick leave benefits	DREAM register [32]	x	x	x	x
Proportion receiving sick leave benefits	DREAM register [32]	x	x	x	x
Psychiatric outpatient contacts	National Patient Register [33]	x	x	x	x
Safety measures and medication use
Deaths by suicide and other reasons	Danish Register of Cause of Death [34]	x	x	x	x
Life-threatening conditions^e	Charlson Comorbidity Index [35]	x	x	x	x
Somatic outpatient visits	National Patient Register [33]	x	x	x	x
Somatic inpatient days and admissions	National Patient Register [33]	x	x	x	x
Psychiatric inpatient days/admissions	National Patient Register [33]	x	x	x	x
Use of medication	Danish Register for Prescription medicine [36]	x	x

Abbreviations: BDI-II Beck Depression Inventory-II, BAI Beck Anxiety Inventory, CSQ-8 Client Satisfaction Questionnaire, GAF-F Global Assessment of Functioning, EQ-5D-3L EuroQol Five Dimensions Questionnaire with Three Levels, INSPIRE-S Recovery support from staff (Support), INSPIRE-R Recovery support from staff (Relationship), PRISE Patient Rated Inventory of Side Effects, PSP Personal and Social Performance Scale, SCL-90-R Symptom Checklist-90-Revised, SDS Sheehan Disability Scale, WHO-5 World Health Organization-5 Well-Being Index
^a SCL-90-R was modified slightly as a reference period of two weeks was used instead of one week. ^b Subscale from the Illness Perception Questionnaire-Revised (IPQ-R). ^c Subscale from the Chronic Disease Self-Efficacy Scales. ^d Side effects were reported for the proportion of participants who used medication. ^e Life-threatening conditions defined by the Charlson Comorbidity Index were assessed using action diagnoses (ICD codes) from the National Patient Register [33]

ISSN: 2731-4553